NeuExcell Therapeutics

NeuExcell Therapeutics is an early-stage gene therapy company headquartered in Pennsylvania, USA, and Shanghai, China. NeuExcell's mission is to treat neurological injuries and neurodegenerative diseases and save patients' lives. The company’s core technology is based on the research achievements of Professor Gong Chen, utilizing AAV gene therapy vectors to express neural transcription factors that directly convert astrocytes within the nervous system into long-term functional neurons, thereby achieving neural repair. NeuExcell’s product pipeline covers major neurological injuries and neurodegenerative diseases, such as stroke, Huntington's disease, ALS, Alzheimer's disease, Parkinson's disease, traumatic brain injury, spinal cord injury, and brain tumors.